Cargando…

CAR T-cell therapy for secondary CNS DLBCL

Management of secondary central nervous system (SCNS) involvement in relapsed or refractory aggressive B-cell lymphomas remains an area of unmet medical need. We report a single-center retrospective analysis of 7 adult patients with SCNS lymphoma (SCNSL) who underwent chimeric antigen receptor (CAR)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahmed, Gulrayz, Hamadani, Mehdi, Shah, Nirav N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2021
Materias:	Stimulus Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714710/ https://www.ncbi.nlm.nih.gov/pubmed/34551065 http://dx.doi.org/10.1182/bloodadvances.2021005292

Ejemplares similares

CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma
por: Siddiqi, Tanya, et al.
Publicado: (2021)

Transformation of FL into DLBCL with a PMBL gene expression signature
por: Loveday, Tristan, et al.
Publicado: (2022)

Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results
por: Jaeger, Ulrich, et al.
Publicado: (2022)

Day 30 SUV(max) predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy
por: Al Zaki, Ajlan, et al.
Publicado: (2022)

Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study
por: Gagelmann, Nico, et al.
Publicado: (2022)

New indications and platforms for CAR‐T therapy in lymphomas beyond DLBCL
por: Iqbal, Madiha, et al.
Publicado: (2021)

Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment
por: Schoeberl, Florian, et al.
Publicado: (2022)

Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment
por: Teipel, Raphael, et al.
Publicado: (2022)

Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse
por: Samra, Bachar, et al.
Publicado: (2021)

COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP
por: Busca, Alessandro, et al.
Publicado: (2022)

CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies
por: Hu, Yixin, et al.
Publicado: (2022)

Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti–PD-1–based therapy
por: Abbas, Hussein A., et al.
Publicado: (2021)

Haptoglobin 1 allele predicts higher serum haptoglobin concentration and lower multiorgan failure risk in sickle cell disease
por: Ruiz, Maria A., et al.
Publicado: (2022)

Genetic variants of PKLR are associated with acute pain in sickle cell disease
por: Wang, Xunde, et al.
Publicado: (2022)

Evaluation of clonal hematopoiesis in pediatric ADA-SCID gene therapy participants
por: White, Shanna L., et al.
Publicado: (2022)

MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma
por: Stroh, Jacob, et al.
Publicado: (2022)

Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy
por: Guillou, Julia, et al.
Publicado: (2022)

Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia
por: Chua, Chong Chyn, et al.
Publicado: (2022)

Lineage switching of the cellular distribution of BRAF(V600E) in multisystem Langerhans cell histiocytosis
por: Milne, Paul, et al.
Publicado: (2022)

Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies
por: Saygin, Caner, et al.
Publicado: (2022)

CAR-T Cell Therapy Shows Similar Efficacy and Toxicity in Patients With DLBCL Regardless of CNS Involvement
por: Shumilov, Evgenii, et al.
Publicado: (2023)

Molecular diagnosis of T-cell lymphoma: a correlative study of PCR-based T-cell clonality assessment and targeted NGS
por: Syrykh, Charlotte, et al.
Publicado: (2021)

Gata2 +9.5 enhancer regulates adult hematopoietic stem cell self-renewal and T-cell development
por: You, Xiaona, et al.
Publicado: (2022)

JMML tumor cells disrupt normal hematopoietic stem cells by imposing inflammatory stress through overproduction of IL-1β
por: Yan, Yuhan, et al.
Publicado: (2022)

Coevolving JAK2(V617F+)relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case
por: Penter, Livius, et al.
Publicado: (2021)

COVID-19 and venous thromboembolism risk in patients with sickle cell disease
por: Singh, Ashima, et al.
Publicado: (2022)

Impact of sickle cell trait on morbidity and mortality from SARS-CoV-2 infection
por: Merz, Lauren E., et al.
Publicado: (2021)

Vemurafenib acts as a molecular on-off switch governing systemic inflammation in Langerhans cell histiocytosis
por: Eder, Sebastian K., et al.
Publicado: (2022)

Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms
por: Alkhateeb, Hassan B., et al.
Publicado: (2022)

Toll-like receptor 4 selective inhibition in medullar microenvironment alters multiple myeloma cell growth
por: Lemaitre, Léa, et al.
Publicado: (2022)

Multiple myeloma cells depend on the DDI2/NRF1-mediated proteasome stress response for survival
por: Chen, Tianzeng, et al.
Publicado: (2022)

Gata2 haploinsufficiency promotes proliferation and functional decline of hematopoietic stem cells with myeloid bias during aging
por: Abdelfattah, Ali, et al.
Publicado: (2021)

Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors
por: Thompson, Ella R., et al.
Publicado: (2022)

Modulating endothelial cells with EGFL7 to diminish aGVHD after allogeneic bone marrow transplantation in mice
por: Dorrance, Adrienne M., et al.
Publicado: (2022)

A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia
por: Broccoli, Alessandro, et al.
Publicado: (2022)

Invariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA
por: Casey, Mika, et al.
Publicado: (2022)

Platelets upregulate tumor cell programmed death ligand 1 in an epidermal growth factor receptor-dependent manner in vitro
por: Guo, Qiuchen, et al.
Publicado: (2022)

CEACAM1 is a novel culture-compatible surface marker of expanded long-term reconstituting hematopoietic stem cells
por: Ansari, Unain, et al.
Publicado: (2022)

Aggressive B-cell lymphoma cases with 11q aberration patterns indicate a spectrum beyond Burkitt-like lymphoma
por: Gebauer, Niklas, et al.
Publicado: (2021)

Role of stem cell transplant in CD30(+) PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2
por: Savage, Kerry J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p22auudiibciejhpa2k68f7cic